1. Home
  2. ULY vs AZTR Comparison

ULY vs AZTR Comparison

Compare ULY & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

N/A

Current Price

$2.04

Market Cap

4.0M

Sector

N/A

ML Signal

N/A

Logo Azitra Inc

AZTR

Azitra Inc

N/A

Current Price

$0.30

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ULY
AZTR
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
4.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ULY
AZTR
Price
$2.04
$0.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.50
$4.00
AVG Volume (30 Days)
68.8K
306.9K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,932,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$0.28
52 Week High
$17.99
$4.33

Technical Indicators

Market Signals
Indicator
ULY
AZTR
Relative Strength Index (RSI) 42.25 33.58
Support Level $1.85 $0.28
Resistance Level $3.13 $0.39
Average True Range (ATR) 0.30 0.03
MACD 0.03 0.00
Stochastic Oscillator 21.01 13.03

Price Performance

Historical Comparison
ULY
AZTR

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: